Johnson & Johnson has received FDA clearance for MONARCH QUEST 3, a software update to its robotic-assisted bronchoscopy system that incorporates AI tools for procedure planning and lung nodule segmentation.
The clearance expands J&J's capabilities in minimally invasive diagnostics and reflects a broader company strategy to lean on MedTech and robotic surgery as growth drivers as older drugs face patent pressure.
The update includes new digital ecosystem features intended to support wider adoption of robotic and AI-guided tools in hospitals.
What happened
Johnson & Johnson received FDA clearance for MONARCH QUEST 3, a software update to its robotic-assisted bronchoscopy platform that adds AI-powered tools for procedure planning and lung nodule segmentation.
Why it matters
The clearance expands J&J's footprint in minimally invasive diagnostics and robotic-assisted surgery, a growth area as the company faces patent expiration on older drugs. The update includes new digital ecosystem features designed to drive broader adoption of robotic and AI-guided tools in hospital and clinical settings.
What to watch
J&J is betting that MedTech platforms and robotic surgery can become a larger earnings engine alongside its core oncology and immunology drugs. Success hinges on converting AI-enabled tools like MONARCH QUEST 3 into meaningful procedure share and attractive margins while managing headwinds in orthopedics and potential tariff or litigation impacts.
Ask the AI about this article →
Johnson & Johnson's FDA clearance for MONARCH QUEST 3 reflects the company's strategic pivot toward MedTech and robotic-assisted procedures as a counterweight to patent expirations and legal risks in its traditional drug portfolio. The company's narrative centers on the bet that new medicines and MedTech platforms can shoulder growth, with robotics and AI positioned as central to that shift. Prior strong performance from acquired cardiovascular units Abiomed and Shockwave, along with broader developments in robotic surgery, underscore this MedTech momentum.
The MONARCH QUEST 3 update sits within a competitive landscape where Intuitive Surgical and Medtronic already operate. By adding AI-powered procedure planning and lung nodule segmentation, along with new digital ecosystem features, J&J is attempting to deepen both clinical value and the utilization of its installed systems. However, the real test is execution: whether AI-enabled tools can translate into material gains in procedure share and margin expansion. The company simultaneously faces pressure from orthopedics headwinds and potential tariff or litigation drag, making the success of this MedTech leg critical to offsetting those risks.
For example, today's edition would include:
AI-summarized, only the topics you pick — one digest a day via Email, Slack, or Discord.
Free · takes 30 seconds · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. Q&As are published on this page for other readers too.
Skild AI has introduced S1, its flagship robot foundation model, which lets robots learn new, complex tasks by…
BHP, the world's largest mining company by market capitalization, has deployed AI across its operations
Team Liquid announced a new five-year extension of its long-running collaboration with Dell Technologies' Alie…
A University of Mississippi study published in Journal of Interactive Advertising found that AI ads succeed wh…
Goldman Sachs Research says AI supply and demand won't balance until the first half of 2028
Lam Research broke ground yesterday on a new lab in Tualatin, Oregon
